We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our
Privacy Policy
.
Yes, I accept
Menu
Corporate Members
E-Library
Twitter
Linked In
Facebook
Instagram
Join
MyESTRO
Search Opener
Search for:
About ESTRO
Membership
School
Workshops
Congresses
Science
Education
Advocacy
Corporate Members
E-Library
Home
Programme
Clinical track: Lung
No date
Session
Clinical track: Lung
Session Code:
9304
Session Type:
Poster
Track:
Clinical
Add to
My Programme
00:00 - 00:00
Prognostic factors in elderly patients with lung carcinoma (NSCLC) treated with curative intent
Presentation Number:
PO-0994
00:00 - 00:00
Is there a learning curve for SABR that affects overall survival outcomes in early stage NSCLC?
Presentation Number:
PO-0988
00:00 - 00:00
Durvalumab treatment after CRT in inoperable stage III NSCLC – a German radiation oncology survey
Presentation Number:
PO-0998
00:00 - 00:00
Radiation therapy for thoracic malignancies: the impact on immune and vascular blood biomarkers
Presentation Number:
PO-0989
00:00 - 00:00
Evaluation of outcome and toxicity of Durvalumab treatment after CRT in inoperable stage III NSCLC
Presentation Number:
PO-0997
00:00 - 00:00
Deciphering the tumor microenviroment based on PD-L1 expression and CD8+ TILs density in LA-NSCLC
Presentation Number:
PO-0999
00:00 - 00:00
Shortened radiation time promotes recovery from lymphopenia in early-stage NSCLC who received SBRT
Presentation Number:
PO-1001
00:00 - 00:00
Multicenter study of stereotactic body radiotherapy in non-small cell lung cancer (KROG 17-09)
Presentation Number:
PO-0993
00:00 - 00:00
Pericardial effusion after radiotherapy for Non-Small Cell Lung Cancer
Presentation Number:
PO-0992
00:00 - 00:00
Prevention of oncologic pulmonary death by control for pulmonary oligometastases treated with SBRT
Presentation Number:
PO-0990
00:00 - 00:00
Impact of residual setup errors after image guidance on heart dose in NSCLC patients
Presentation Number:
PO-0991
00:00 - 00:00
Early mortality in stage III NSCLC after radical non-surgical therapy following ESMO guidelines
Presentation Number:
PO-0996
00:00 - 00:00
Impact of the dose outside the PTV on distant recurrence in coplanar and non-coplanar lung SBRT
Presentation Number:
PO-0995
00:00 - 00:00
Multicentric restrospective analysis of safety of SBRT to centrally located lesion of the lung
Presentation Number:
PO-1000
00:00 - 00:00
Long term outcomes and lung function evolution of primary lung tumors treated with Cyberknife SABR
Presentation Number:
PO-1019
00:00 - 00:00
Does MR imaging give us advantage in contouring thoracic structures for Cardiac SABR?
Presentation Number:
PO-1020
00:00 - 00:00
Stereotactic radiotherapy for unresectable locally advanced non small cell lung cancer
Presentation Number:
PO-1021
00:00 - 00:00
Clinical-dosimetric assessment with Prodvh software after adjuvant radiotherapy for MPM
Presentation Number:
PO-1022
00:00 - 00:00
Impact of biological features in radiosurgery for Brain metastases from Non Small Cell Lung Cancer
Presentation Number:
PO-1023
00:00 - 00:00
Fractionated RT is equally effective but less toxic than SBRT for central early-stage NSCLC
Presentation Number:
PO-1024
00:00 - 00:00
Prognostic factors for PFS and OS in radically treated patients with oligometastatic NSCLC
Presentation Number:
PO-1025
00:00 - 00:00
Disease natural history of lung oligometastatic colo-rectal cancer patients treated with SBRT
Presentation Number:
PO-1027
00:00 - 00:00
Consolidation therapy with Durvalumab after radical CRT in stage IIII NSCLC: a preliminar analysis
Presentation Number:
PO-1028
00:00 - 00:00
Preliminary analysis of patient cohorts treated pre vs post approval of consolidation IO in LA-NSCLC
Presentation Number:
PO-1029
00:00 - 00:00
Early outcomes of stereotactic MR-guided adaptive radiation therapy in 54 high-risk lung tumors
Presentation Number:
PO-1002
00:00 - 00:00
Challenges on the CT follow-up after SBRT to early stage NSCLC
Presentation Number:
PO-1030
00:00 - 00:00
Initial report on feasibility of Hypo-IGRT in stage IIB-III NSCLC pts with poor PS & lung function
Presentation Number:
PO-1031
00:00 - 00:00
Clinical Features and Treatment Outcome of Resectable Pulmonary Large Cell Neuroendocrine Carcinoma
Presentation Number:
PO-1032
00:00 - 00:00
The result of type C thymic epithelial tumor: multimodality treatment combined with radiotherapy
Presentation Number:
PO-1033
00:00 - 00:00
Preliminary results of SRS for a lung tumor: a single-arm phase 2 study in a single institute
Presentation Number:
PO-1003
00:00 - 00:00
Continuous Positive Airway Pressure (CPAP) use for Motion management in Lung SBRT
Presentation Number:
PO-1004
00:00 - 00:00
Influence of PTV underdosage on local control in patients with central NSCLC treated with SBRT
Presentation Number:
PO-1005
00:00 - 00:00
Immunotherapy related pneumonitis correlates with radiomics in NSCLC patients treated with Nivolumab
Presentation Number:
PO-1006
00:00 - 00:00
Predictors of radiation pneumonitis in early stage lung cancer treated with SABR.
Presentation Number:
PO-1007
00:00 - 00:00
Predictive dosimetric parameters of lymphopenia in stage III NSCLC patients with chemoradiation
Presentation Number:
PO-1008
00:00 - 00:00
Salvage Re-irradiation for Recurrent Lung Cancer: Treatment outcomes and toxicity analysis
Presentation Number:
PO-1009
00:00 - 00:00
Stereotactic Body Radiation Therapy is safe and effective for ultracentral lung lesions
Presentation Number:
PO-1010
00:00 - 00:00
Impact of radiation therapy on immunotherapy efficacy in metastatic non-small cell lung cancer.
Presentation Number:
PO-1011
00:00 - 00:00
Prognostic Value of Anemia in Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy
Presentation Number:
PO-1012
00:00 - 00:00
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC.
Presentation Number:
PO-1013
00:00 - 00:00
Mitigating breathing motion with nasal high flow therapy (NHFT) in lung cancer: A prospective study
Presentation Number:
PO-1014
00:00 - 00:00
SBRT after CT-RT for stage III unresectable NSCLC with peripheral primary tumor (GFPC 01-14 study)
Presentation Number:
PO-1015
00:00 - 00:00
Efficacy and safety profile of Stereotactic Ablative Radiotherapy (SABR) for multiple lung primaries
Presentation Number:
PO-1016
00:00 - 00:00
Poor Diffusing Capacity for Carbon Monoxide (DLCO) is associated with worse survival post SABR
Presentation Number:
PO-1017
00:00 - 00:00
Lung SABRT treatment in oligometastatic patients, a prospective review
Presentation Number:
PO-1018
E-Mail Address
Please enter a user name
Password
Cancel
Forgotten Password
Create MyESTRO Account
i
Please log in to add this session to your programme.